Medicines affordability in the US
Some people with diabetes in the US are increasingly finding it hard
to pay for their healthcare, especially those uninsured and in
high-deductible healthcare plans. This is not acceptable.
In line with our social responsibility, we have launched initiatives
and programmes offering people living with diabetes in the US insulin
affordability solutions. These include:
- Making low-cost human insulin available at Walmart
for around $25 per vial. This offering has been running for
almost two decades and has recently been made available in other
national pharmacy chains through programmes with CVS and ESI. Around
500,000 Americans are using our human insulin through these
- Offering co-pay cards to help defray patient
- Providing a patient
assistance programme, which in 2018 provided free insulin to
nearly 50,000 people with diabetes. Through the programme, an
individual with an annual income up to 49,960 US dollars, and a
family of four with a combined annual income up to 103,000 US
dollars, may qualify for free Novo Nordisk medicines - including all
of our insulin products.
My$99Insulin offering means all patients can purchase up to
three vials or two packs of
of any combination of insulins from Novo Nordisk Inc. for $99.
- Making authorized generics of two of our modern insulins made by
new Novo Nordisk A/S US company, Novo Nordisk Pharma, Inc.,
available at pharmacies within 1-3 business days at 50 percent off
the list price.
- An immediate, one-time insulin supply
option available for people facing an acute need when more time is
needed to identify a long-term sustainable solution.
The complexity of the US healthcare system means that arriving at
solutions that ensure affordable access to medicines for all is not
straightforward. However, we believe that with collaboration across
all parties in the system, sustainable solutions can be achieved.
We want to be part of a solution and we are actively working with
all parties in the US healthcare system to find ways that reduce the
burden on patients both in the short-term and for longer-term reform.
Find out more about
NovoCare(R) and our insulin affordability